Jingbo Yi

414 total citations
15 papers, 283 citations indexed

About

Jingbo Yi is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Jingbo Yi has authored 15 papers receiving a total of 283 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 3 papers in Genetics and 3 papers in Oncology. Recurrent topics in Jingbo Yi's work include Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Jingbo Yi is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Jingbo Yi collaborates with scholars based in United States, Japan and Switzerland. Jingbo Yi's co-authors include Joyce O’Shaughnessy, Véronique Dièras, D.W. Miles, Javier Cortés, Bruce Crawford, Kensei Tobinai, Arijit Ganguli, Murali Sundaram, Cynthia L. Nicholson and Yihua Gu and has published in prestigious journals such as PLoS ONE, The Journal of Urology and Annals of Oncology.

In The Last Decade

Jingbo Yi

14 papers receiving 270 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jingbo Yi United States	7	170	81	76	44	40	15	283
Ana B. Galván Spain	9	112 0.7×	138 1.7×	75 1.0×	45 1.0×	50 1.3×	13	307
Edgardo R. Parrilla Castellar United States	6	93 0.5×	48 0.6×	29 0.4×	44 1.0×	110 2.8×	9	257
M K Heatley United Kingdom	11	83 0.5×	31 0.4×	36 0.5×	37 0.8×	34 0.8×	17	258
Inês Vasconcelos Germany	7	121 0.7×	23 0.3×	74 1.0×	39 0.9×	23 0.6×	16	362
Mahsa Vahdatinia United States	9	87 0.5×	40 0.5×	76 1.0×	25 0.6×	50 1.3×	15	223
Kortnye Smith Australia	7	95 0.6×	56 0.7×	23 0.3×	18 0.4×	38 0.9×	11	210
Shu-Sen Wang China	5	175 1.0×	45 0.6×	109 1.4×	56 1.3×	99 2.5×	8	300
Monika Šedivcová Czechia	10	120 0.7×	38 0.5×	45 0.6×	22 0.5×	41 1.0×	18	222
Clay M. Anderson United States	9	134 0.8×	73 0.9×	48 0.6×	17 0.4×	36 0.9×	13	296
D-S Bae South Korea	9	72 0.4×	62 0.8×	63 0.8×	10 0.2×	24 0.6×	20	372

Countries citing papers authored by Jingbo Yi

Since Specialization

Citations

This map shows the geographic impact of Jingbo Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingbo Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingbo Yi more than expected).

Fields of papers citing papers by Jingbo Yi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingbo Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingbo Yi. The network helps show where Jingbo Yi may publish in the future.

Co-authorship network of co-authors of Jingbo Yi

This figure shows the co-authorship network connecting the top 25 collaborators of Jingbo Yi. A scholar is included among the top collaborators of Jingbo Yi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingbo Yi. Jingbo Yi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Loomans‐Kropp, Holli A., et al.. (2025). Perceptions of COVID-19 risk among individuals with preexisting health conditions. PLoS ONE. 20(5). e0320792–e0320792.

Komine, Mayumi, et al.. (2023). A discrete choice experiment on oral and injection treatment preferences among moderate‐to‐severe psoriasis patients in Japan. The Journal of Dermatology. 50(6). 766–777. 15 indexed citations

Iida, Shinsuke, Tadao Ishida, Toshihiro Miyamoto, et al.. (2022). MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation. International Journal of Hematology. 116(3). 411–422. 1 indexed citations

Makita, Shinichi, et al.. (2022). Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis. PLoS ONE. 17(5). e0269169–e0269169. 6 indexed citations

Uchiyama, Makoto, Kaoru Ito, Yasuyuki Okumura, et al.. (2022). Medical Costs Associated with Insomnia Treatment with Suvorexant Monotherapy in Japan: Results from a Retrospective Cohort Study Using a Large-Scale Claims Database. Drugs - Real World Outcomes. 9(2). 219–229. 1 indexed citations

Makita, Shinichi, et al.. (2021). Economic Burden in Treated Japanese Patients with Relapsed/Refractory Large B-Cell Lymphoma. Future Oncology. 17(33). 4511–4525. 7 indexed citations

Nosaka, Kisato, et al.. (2021). Systematic review of survival outcomes for relapsed or refractory adult T‐cell leukemia‐lymphoma. European Journal Of Haematology. 108(3). 212–222. 7 indexed citations

Tobinai, Kensei, et al.. (2020). Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS ONE. 15(8). e0237509–e0237509. 24 indexed citations

Richards, Kyle A., Shih‐Wen Lin, Christina Louise Derleth, et al.. (2020). Increased Bacillus Calmette-Guérin Treatment Intensity Associated With Improved Outcomes in Elderly Patients With Non–Muscle-invasive Bladder Cancer in United States Clinical Practice. Urology. 145. 172–180. 6 indexed citations

10.

Tobinai, Kensei, et al.. (2020). Comparative Effectiveness Study of Chemotherapy in Follicular Lymphoma Patients in the Rituximab Era: A Japanese Claims Database Study. Future Oncology. 17(4). 455–469. 5 indexed citations

11.

Richards, Kyle A., Shih‐Wen Lin, Christina Louise Derleth, et al.. (2019). PD18-09 INCREASED BACILLUS CALMETTE-GUÉRIN TREATMENT INTENSITY ASSOCIATED WITH IMPROVED OUTCOMES IN ELDERLY PATIENTS WITH NON–MUSCLE-INVASIVE BLADDER CANCER. The Journal of Urology. 201(Supplement 4). 1 indexed citations

12.

Luhn, Patricia, Jane Yuet Ching Hui, Jingbo Yi, et al.. (2019). Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer. Journal of Comparative Effectiveness Research. 8(14). 1173–1185. 9 indexed citations

13.

Hamzavi, Iltefat, Murali Sundaram, Cynthia L. Nicholson, et al.. (2017). Uncovering burden disparity: A comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. Journal of the American Academy of Dermatology. 77(6). 1038–1046. 41 indexed citations

14.

Corvino, Frank A., et al.. (2017). P3.01-086 Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States. Journal of Thoracic Oncology. 12(11). S2235–S2236. 1 indexed citations

15.

Miles, D.W., et al.. (2013). First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Annals of Oncology. 24(11). 2773–2780. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact